41
Company’s Presentation August 2011

Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

Embed Size (px)

Citation preview

Page 1: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

Company’s PresentationAugust 2011

Page 2: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

2

Disclaimer

This presentation has been prepared by DIOD OJSC (the "Company“, “Group” or “DIOD”). By attending the meeting where the presentation is made, or by reading the presentation, you agree to the limitations and notifications set out below.

This presentation is strictly confidential to the recipient and may not be reproduced or redistributed, passed on, or the contents otherwise divulged, directly or indirectly, to any other person or published in whole or in part for any purpose. Failure to comply with this restriction may constitute a violation of applicable securities laws.

This presentation has been prepared solely for your information in connection with the possible offering of securities of the Company.

The presentation does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company or any member of its group nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company or any member of its group, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Any person considering the purchase of any securities of the Company must inform himself or herself independently based solely on the Company's prospectus and any amendments or supplements thereto before taking any investment decision. The prospectus, when issued, may contain information different from the information contained in this presentation.

This presentation includes forward-looking statements. These forward-looking statements include statements concerning targets, plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The words "believe", "expect", "anticipate", "intend", "estimate", "forecast", "project", "will", "may", "should" and similar expressions identify forward-looking statements. Forward-looking statements include statements regarding: strategies, outlook and growth prospects; future plans and potential for future growth; liquidity, capital resources and capital expenditures; growth in demand for products; economic outlook and industry trends; developments of markets; the impact of regulatory initiatives; and the strength of competitors.

By their nature, forward-looking statements involve risks and uncertainties, because they relate to events and depend on circumstances that may or may not occur in the future. The forward-looking statements in this presentation are based upon various assumptions, many of which are based, in turn, upon further assumptions, including, without limitation, data available from third parties.

Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond the Company's control, and the Company may not achieve or accomplish these targets, expectations, beliefs or projections. The Company cautions you that forward-looking statements are not guarantees of future performance and that its actual results of operations, financial condition and liquidity and the development of the industry in which the Company operates may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. These forward looking statements speak only as at the date as of which they are made and, neither the Company, nor any of its agents, employees or advisors intend or have any duty or obligation to supplement, amend, update or revise any of the forward-looking statements contained in this presentation to reflect any change in the Company's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. The Company does not undertake any obligation to review or confirm analysts' expectations.

This presentation is not directed to or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

This presentation is not an offer or solicitation to purchase or subscribe for securities in the United States. The securities of the Company have not been registered under the US Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States or to or for the account or benefit of US persons (as such terms are defined in Regulation S under the Securities Act) unless registered under the Securities Act or pursuant to an exemption from such registration. The Company does not intend to register its securities under the Securities Act or to conduct a public offering of the securities in the U.S.

This presentation does not constitute an offer to the public or an advertisement of securities in the Russian Federation, and is not an offer or an invitation to make offers to purchase securities in the Russian Federation, and must not be passed on to third parties or otherwise made publicly available in the Russian Federation.

This communication is only directed (i) at persons who are outside the United Kingdom, (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act of 2000(Financial Promotion) Order 2005, as amended (the "Order") or (iii) other persons to whom it may be lawfully communicated, falling within Article 49 (a) to (d) of the Order (all such persons together being referred to as "Relevant Persons"). Any person who is not a Relevant Person should not act or rely on this communication or any of its contents. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. Other persons should not act or rely on this document or any of its contents.

NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN.

Failure to comply with the restrictions set out in this Disclaimer may constitute a violation of applicable securities laws or may otherwise be actionable.

Page 3: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

3

Table of Contents

I. Company Overview

II. Investment Highlights

III. Strategy and directions of development

IV. Key Financial Indicators

APPENDIX

1. Financial Statements For The Years of 2007-2010

2. Key Financial Parameters Forecast

3. Company's Product Portfolio

3

9

21

26

31

35

37

Page 4: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

Company OverviewSection 1

Page 5: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

5

DIOD at a Glance

■ DIOD, one of the founders of the Russian consumer healthcare market, has started production of consumer healthcare and pharmaceutical products in 1997

■ As of the end of 2010, the Company was the forth largest player in the Russian consumer healthcare market according to the volume of sales 5,2% on the market of nutritional supplements*

■ Company’s product portfolio includes leading brands in the Russian consumer healthcare market

Capilar, the Company’s core brand with a market share of 2.1%*, has been the leading and best-selling consumer healthcare brand in Russia since 2006

The Company’s other brands include Phase 2, Iod-Aktiv, Viardo Forte, Stella

■ The Company is the world’s largest producer of dihydroquercetin (DHQ)

■ The Group currently comprises 11 subsidiaries involved in production and distribution of consumer healthcare products, pharmaceuticals, medical and ecological equipment and innovative substances

■ The Company boasts an efficient distribution chain, which covers almost 100% of the territory of Russia. In 77 regions (93% of the total area in Russia) the Company enjoys partnership relationships with regional distributors. DIOD also operates its own retail network, which is comprised of 6 stores

■ The Group employs 565 people (incl. 20 R&D** employees)

■ In June 2010, the Company did IPO and became public on MICEX’s sector of “ Market of Innovations and Investments”. There were placed 10% of shares among private investors. After IPO finished, Company’s capitalization was about $100 mln.

■ In July Company’s shares were included in the calculation base of the index "MICEX-Innovation» (MICEX INNOV)

Group’s structure

Key financial parameters

(*) according to DSM Group marketing agency, 2010(**) – Research and Development

Source: Company’s audited consolidated IFRS financial statements for the years of 2007-2010

CJSC Ametis

Taxifoliya, Ltd.

CJSC Taiga-Gaz

Flavir, Ltd.

Taxifoliya, Ltd.

CJSC Ametis

OJSC Diod

CJSC Ecologia Pitaniya

CJSC Olyfen

CJSC AmetisVitamedis AG

Gruppa Kompanij SIBLAREX, Ltd.

CJSC Vega Pharm

Ecologia Zhizni, Ltd.

Source: Company data

OJSC Diod

Mln. rub. 2007 2008 2009 2010

Revenue 1 624 1 730 1 559 1 548Growth rate 14% 7% -10% -1%Gross profit 953 1 056 833 796Gross margin 59% 61% 53% 51%EBITDA 417 389 332 359EBITDA margin 26% 23% 21% 23%Net profit 232 303 374 163Net margin 14% 17% 24% 11%

Net profit less M&A 229 200 109 131Net margin less M&A 14% 12% 7% 8%

Page 6: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

6

Sales Structure*

Nutritional Supplements Health CosmeticsPharmaceuticals Other

■ Nutritional supplements – food supplements for oral consumption, containing natural nutritive and biologically active ingredients of plant, animal, microbial and mineral origin

■ Major products:

• Capillar (cardiovascular system) - brand #1 in Russia in the consumer healthcare market

• Viardo / Viardo Forte (men’s health)

• Iod-Aktiv (thyroid gland function sustentation)

• Phase 2 (weight control)

■ Health cosmetics – cosmetics, creams, balms, sprays and other products for application to body surfaces

■ Combine aesthetic and therapeutic properties

■ Major products:

• Artro-Aktiv health cosmetics (musculoskeletal system health)

• Capillar health cosmetics (venous insufficiency, hydrops, bruises)

• Spray-tonic Okulist for eyelid and eye contour (vision correction)

■ Original and generic pharmaceuticals production

■ The Company started pharmaceuticals’ production in 2008, when acquired Olyfen and Vega Pharm

■ Major products:

• Gipoksen (hypoxia treatments, OTC)

• Mebix (depression, neurosis treatment, Rx)

• Orvirem (antiviral treatment, Rх)

■ The Company has a license for rendering medicine services. Since 2001, the Company operates Mir Ekologii medical center

■ Own retail network (6 stores, operating under Mir Ekologii brand name)

■ Online store operations

www.ecvita.ru

(*) highlighted figures refer to the share of the product group in the total Group’s revenue. Figures in the circles indicate sales of the product group in 2009Source: Company data

RUB 938 mln

Equipment

■ Technology for diagnosis and monitoring of, and relief from, health conditions

■ Major products:

• Cardiovisor (heart condition screening)

• Georgy (silver ion water ioniser)

• Svetovit (infrared therapy)

• Elion-132 (aeroionization profilactics equipment)

• Urinary iodine analyzer

• Minimax (blood hemophoresis measurement)

Consumer Healthcare

RUB 187 mln

RUB 155 mln

RUB 19,5 mln

RUB 247 mln

Page 7: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

7

Top-15 Company’s Products

Source: Company data

Top - 15 Company's Brands

Brand TypeSales 2010, RUB mln

Sales share, %

Segment

Capilar pills cardiovascular system 305,8 20%

Capilar Cardio cardiovascular system 18,6 1%

Phase-2 weight control 193,7 13%

Viardo men's sexual health 71,5 5%

Viardo Forte men's sexual health 81,5 5%

Stella women's sexual health 72,5 5%

Iodine-active vitamin&mineral supplements 23,6 2%

Iodine-active 100 vitamin&mineral supplements 14,9 1%

Calcium-active vitamin&mineral supplements 28,0 2%

Okulist eyes health 27,1 2%

Selenium-active vitamin&mineral supplements 38,0 2%

Arto-active healthy vessels 28,2 2%

Chistovit health of gastrointestinal tract 23,0 1%

Segment of pharmaceuticals

Orvirem® antiviral 51,5 3%

Dikvertin® antioxidant 33,9 2%

Segments' total   1 011,9 65%

Others   536,2 35%

Total   1 548,1 100%

Page 8: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

8

Production Facilities

Blagoveshensk

CJSC Ametis

■ Russian and world’s largest producer of taxifolin

Production capacity:

■ 11 tons of taxifolin annually

4Belgorod

CJSC Taxifoliya

■ Largest Russian company, engaged in taxifolin chromatographic purification

Production capacity:

■ Purification of 45 tons raw taxifolin annually

2 Irkutsk

CJSC Taiga-GAZ

■ Producer of raw taxifolin with purity factor of 75-80%

Production capacity:

■Up to 10 tons annually

Flavir, Ltd.

■ Chromatographic purification of raw taxifolin up to the purity factor of 90-92% for producing pharmaceuticals

Production capacity:

■Up to 5 tons annually

3

Moscow1

43

2Belgorod

IrkutskBlagoveshensk

Russia

Source: Company data

The Company acquired a land plot – 5,8 hectares in Podolsk, where it plans to build a new modern manufacturing and warehouse facilities and relocate R&D and manufacturing departments from Moscow

Moscow

Paveletskaya

OJSC Diod (Paveletskaya)

■3 workshops with 5 production lines specialized in production of consumer healthcare products

■1 workshop producing ecology equipment

Production capacity:

■1.8 bln pills (0.25g pills), 50 mln blisters annually

■Capacity utilization amounted to 55-60% in 2009

CJSC Olyfen (Voikovskaya)

Production facility:

■ 2 workshop producing pills and syrups

■ An additional workshop is planned to be launched

Production capacity:

■ 1.8 mln blisters, 48,000 liters syrup and 300 mln pills annually

1

Voikovskaya

Page 9: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

9

History Milestones

Company's establishment

1994

■Company's privatization on the basis of territory #2 (workshop #4) of Sapfir Company

1995

■DIOD – leading producer of uncooled photodiods

■Company's management decides to switch from B2B market to consumer healthcare (B2C) market

■Serial launch of Elion-132, developed in association with Research Institute of First Aid n.a. N.V.Sklifosovsky

■Launch of Mir Ekologii retail chain

1996

■Launch of 1st modification of Georgy equipment, developed in association with the Central Military Hospital n.a. N.N.Burdenko

1994 - 1996 2007 - 20111997 - 2002

Enter Russian consumer healthcare market

1997

■Founding of a “Ekologiya Pitaniya” subsidiary, producing consumer healthcare products

■Launch of Spirulina BEL (nutritional supplement) production

1998

■Start of design and development of production workshop, specializing in production of healthcare products on the territory of DIOD

1999

■Launch of production of Dolgolet and Iod-Aktiv (nutritional supplements), developed in association with the Medical Radiological Center of the Russian Academy of Medical Sciences

2000

■Launch of Viardo (nutritional supplement) production

2001

■Launch of Capillar (nutritional supplement) production

2002

■Launch of Selen-Aktiv (nutritional supplement) production, developed in association with the Medical Radiological Center of the Russian Academy of Medical Sciences

2003 - 2007

Leadership in consumer healthcare market

Diversification

2003

■DIOD is the leading player in the consumer healthcare market

■Launch of Kaltcy-Aktiv (nutritional supplement) production, developed in association with Moscow Stomatological University and Okulist

2004

■Launch of health cosmetics production – Capillar body cream-balm

2005

■Launch of Kapsula Artro-Aktiv (nutritional supplement), oil balm Artro-Aktiv Warming, cream-balm Artro-Aktiv Alimentary production

2006

■Launch of Capillar leg gel production

2007

■Procurement of exclusive rights on the territory of Russia & CIS for producing of Phase 2 - Calories blocker; signing of an exclusive distribution agreement with Pharmachem, USA

Launch of pharmaceuticals production

Innovation development

2008

■Launch of Phase 2 production Acquisition and consolidation of Olyfen and Vega Pharm pharmaceutical companies

■Start of nanotechnology development

2009

■Procurement of Security certificate (GRAS), USA for taxifolin

■Acquisition of controlling equity interest in CJSC Flavir and CJSC Taiga-GAZ, producing Dikveretin (pharmaceutical)

■Launch of Agralin D (nutritional supplement) production, developed in association with the Flu Institute of the Russian Academy of Medical Sciences

■Launch of Okulist Chernika (nutritional supplement) production, developed in association with the Russian Association of Children Ophthalmologists

■Development of Okulist sprey in association with the Institute of Biomedical Problems

2010

■Launch of Stella (nutritional supplement) production, developed in association with the Russian Association of Obstetricians /Gynaecologists

■Registration of urinary iodine analyzer MIKON-IOD

■Development of medical paste for tooth filling using nanotechnology

2011

■Launch of production of medical and prophylactic food with the brand “Capilar”.

■Getting the certificate Novel Food for the substance dihydroquercetin (DHQ)

Source: Company data

Page 10: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

Investment HighlightsSection 2

Page 11: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

11

Key Investment Highlights

Portfolio of recognizable brands

Efficient multi-level distribution network

High corporate governance standards

Professional and entrepreneurial

management team

■ Senior management team that determines the Company’s strategic development

■ Strong track record of converting concepts and scientific and technical knowledge into commercially viable products that cater to specific market needs

■ Ability to transform the Company’s direction at different development stages

■ Adherence to best corporate governance practices

Innovative leader of the Russian consumer

healthcare market

Strong R&D capabilities

■ Second-largest player in the Russian consumer healthcare market (according to DSM)

■ Focus on the fastest growing market segments – cardiovascular systems, weight control, men’s and women’s health, musculoskeletal system, central nervous system, vision

■ Well positioned to re-register nutritional supplements and health cosmetics as medical nutrition and pharmaceutical products, enabling the Company to capture additional market share

■ First company in Russia which got the expert conclusion from the Russian Academy of Medical Sciences and Research Institute of Nutrition for the use of clinical nutrition for prevention and as a component of complex therapy coronary heart disease

■ Portfolio of recognizable and demanded brands in the market

■ Since 2006, Capillar has been the best-selling consumer healthcare product in Russia

■ Product portfolio includes such well-known brands as Viardo, Okulist, Blocker of calories Phasa-2, Iod-Aktiv, Artro-Aktiv, Stella

■ Team of highly skilled R&D staff, including 10 Ph.D. professionals with comprehensive industry experience

■ Established partnerships with more than 50 Russian and international scientific research institutes, clinical centers, research and testing laboratories, and professional groups

■ Wide development portfolio of compounds , products/substances that have already passed pre-clinical and clinical trials

■ Product distribution network covers all 83 Russian regions (100%), with established regional distribution partnerships in 77 Russian regions (93%)

■ High penetration of each regional market without dependency on any single distributor

■ Own retail chain, comprising 6 branch stores and an online store

■ Cooperation with leading industry associations and access to key opinion-leaders

■ 3 independent Board Directors’ protecting shareholders’ interests

■ Transparent corporate structure and business-model, supported by IFRS financial accounts

■ Management’s ISO 9001:2008 certified

1

2

3

5

4

6

Page 12: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

12

■ Focus on the most perspective market segments

■ Joint R&Ds with the leading Russian institutes and associations, such as the Flu Institute of the Russian Academy of Medical Sciences and the Russian Association of Obstetrician-Gynecologists

■ Clinical trials done in association with the leading Russian research institutes and clinics

■ Promotion support from NGOs and professional associations: Russian Association of Honored Doctors, Restorative Medicine Institute, Nation Health League, Russian Association of Children Ophthalmologists

■ Promotion of the Company’s products through its own medical equipment

■ Developed methodological recommendations for use across medical activities

■ 6 registered medical technologies for the usage of the Company’s products in medical practices

Nutritional Supplements (NS)

Russian Consumer Healthcare Market Leader (1/2)

Page 13: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

13

Russian Consumer Healthcare Market Leader (2/2)

Health Cosmetics

■ As of 2010, the Company’s market share in the health cosmetics market amounted to 3.4%

■ Ability to leverage off some of the best selling brands to produce a number of successful brand families

■ The Company registered 3 medical technologies for the usage of health cosmetics products in medical practices

Equipment

■ The Company produces diagnostic and therapeutic medical equipment

■ Medical equipment allows the Company to effectively promote other Company’s products as well as to demonstrate effectiveness of the Company’s consumer healthcare products

■ The Company registered 2 medical technologies for the usage of its products in medical practices (on the basis of Georgy water ionizer and Svetovit infrared therapy equipment)

Source: DSM Group data

Page 14: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

14

Portfolio of Recognizable Brands

Capillar

■ Cardiovascular system disease prevention

■ NS #1 in Russia since 2006

Viardo

■ Erectile dysfunction treatment

■ NS #3 for erectile dysfunction treatment in 2009

Calories blocker – Phase 2

■ Weight control, blocks complex carbohydrate fixation

■ NS #2 for weight control in 2009

Iod-Aktiv and Iod-Aktiv 100

■ Thyroid gland function sustentation

■ NS #2 in Russian in thyroid gland function sustentation in 2006

Artro-Aktiv

■ Diarthroses treatment

■ NS #2 for diarthroses treatment in 2009

Other brands

KALTCY-AKTIVRegulation of calcium

metabolism

SELEN AKTIVAnti-oxidant, radio

protector

OKULISTVision correction

Araglin DFlu and acute

respiratory viral infection

prevention

DolgoletGeneral tonic action

StellaWomen reproductive

system health

Source: Company data, DSM Group

Page 15: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

15

Clinical nutrition (1/2)

■ JSC DIOD opens a new manufacturing segment – clinical nutrition.

■ This is relatively new segment of products for health for Russia. Production of clinical and functional nutrition is the main brand of Healthcare industry.

■ JSC DIOD has got Certificate of State registration of clinical (dietary) nutrition “Cardio capilar”, “Capilar 120/80”.

■ In the nearest future JSC DIOD is planning to produce clinical nutrition for use together with cure as a complex therapy of treatment the following diseases: arthrosis, vision diseases, insufficiency of iodine, diseases of female reproductive system.

“Capilar 120/80” is for:

■ strengthening of vascular walls and improvement of functional state of cardiovascular system;

■ normalization of arterial pressure and heart rate;

■ reduction of risk of development of ischemic heart disease, stroke, hypertension, atherosclerosis.

“Cardio capilar” is for:

■ reduction of risk of development of ischemic heart disease and its complications (heart attack and stroke), cardiopulmonary insufficiency;

■ Reduction of inclination to trombus’ formation, normalization of microcirculation of blood, improvement of functional state of cardiovascular system;

■ Increase of physical endurance of heart muscle and tolerance to physical activity, reduction of period of rehabilitation after acute old myocardial infarction.

Certificates of state registration of clinical (dietary) nutrition ‘’Cardio capilar with coenzyme Q10”, “Capilar 120/80”.

Consumer package

For realization to people who suffer from high arterial pressure

and hypertension

For realization to people as specialized foodstuff for dietary

(clinical and prophylactic) nutrition for prevention and complex therapy

of ischemia

Page 16: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

16

Clinical nutrition (2/2)

■ According to the WHO data more than 17 mln people die annually in the world from cardiovascular diseases, more than 1 mln – in Russia;

■ According to the GNITS of prophylactic medicine of Ministery of Healthcare and Social Development in Russia about 10 mln capable of working people have stable forms of Ischemic heart disease;

■ More than 40 mln people of patients in Russia suffer from arterial hypertension;

■ According to the official data of Russian Healthcare Organization in Russia 2,4 mln people are registered with the chronic obstructive disease of lungs, but according to the epidemiologic evidence this figure could be about 16 mln people.

■ World’s market of clinical and prophylactic nutrition is developing intensively, and annually it is increasing for 15-20%.

■ Federal authorities give annually from the federal budget in USA budget millions of dollars on subvention for enrichment of nutrition products with natural active components. About 40% of functional products belongs to USA according to official data.

■ The volume of probiotic products and products that have food supplements in France has increased in 350 times.

■ It is considered that till 2015 the market will be more than 30% of all the selling nutrition products.

Situation in Russia

Valuation of global market

Millions, rubles

Page 17: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

17

■ 34 registered patents

■ 9 patents under registration

■ 47 brand name registration certificates

■ 1 prize winner of the Russian Government

■ 2 members of the Russian Academy of Natural Science

■ 5 Doctors of Science

■ 6 PhDs

Human resources Intellectual property

■ Established partnership with 53 leading R&D institutions, clinical centers, research and testing laboratories and professional groups

■ Unique bioactivity and toxicological safety test laboratory, certified by the Federal Service on Surveillance for Consumer Rights Protection and Human Well-being (“Rospotrebnadzor”)

■ 7 methods of bioactivity and safety measurement

■ Research preparative chromatography laboratory

■ Developed 6 state reference standards

Optimal Platform for Innovation, Product Development and Commercialization

Developed, registered and launched*:

■4 medical equipment products

■29 new unique medical products, including 3 finished products and 8 market leaders

Developed and registered:

■6 new medical technologies

■15 items of original raw materials, including 2 active pharmaceutical compounds

■4 state reference standards

Developed and under registration:

■8 finished products

■6 original active pharmaceutical compounds

■8 state reference standards

Own R&D laboratories Outsourced R&D facilities

(*) over the last 10 yearsSource: Company data, DSM Group

Page 18: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

18

1999

2005 2006 2007 2008 2009

2000 2001 2003 20042002

• Dolgolet• Iod-Aktiv• Mitomin• Yantavit

• Elion 132• Georgy silver ion water

ionizer

• Viardo • Capillar (pills)• Enerlit• Selena VEL

• Selen-Aktiv• Gepavit• Chistovit VEL

• Calcium-Aktiv• Dushevny Chai

• Body cream-bal Capillar

• Artro-Aktiv blisters • Viardo-forte• Iod-Aktiv Forte

• Araglin D• Okulist-chernica• Chistovit forte• Cardio-Capillar• Q10• Stella• Products for thyroid gland

function sustentation • Spasin

• Calories blocker – Phase 2• L-carnitine

• Artro-Aktiv warming• Artro-Aktiv alimentary

• Capillar leg gel

• Liquid patch

• T-Iod

• Infrared therapy equipment Svetovit

• Medical technology with Artro-Aktiv balm

• 4 medical technologies applying:

NS Okulist Artro-Aktiv balm Medical equipment

Cardiovisor Svetovit

• Gipoksen• Orvirem• Mebiks

- Nutritional Supplements - Health cosmetics - Pharmaceuticals - Medical equipment - Medical technology

Longstanding R&D Experience

Page 19: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

19

48%

18%

17%

13%4%

Developed Distribution Network

■ The Company has developed efficient multi-level distribution network (176 partners), comprising the following levels:

National distributors of pharmaceutical products: CIA, Katren, Apteka-Holding, Protek, Rosta (with presence in all Russian regions)

National distributors of consumer healthcare products Regional distributors of pharmacy products Regional representatives Independent drug-store chains Retail chains

■ Multilevel structure of the distribution network allows to limit dependency on any single distributor and to rapidly achieve high penetration levels of each regional market

■ Successful distribution of the Company’s products through Metro Cash&Carry chain showed the potential of retail chains as a new distribution channel

The Company plans to further enhance its presence in retail chains and currently holds negotiations with Auchan, X5 Retail Group (Perekrestok and Pyaterochka stores), Magnit, Giperglobus and Zelgros

■ Own retail stores enable the Company to pilot launch of new healthcare products

Sales breakdown by region

Distribution channels

Source: Company data for the year of 2009

Far East region

Siberian region

Urals region

North-West region

Central region

Volga regionRUB 38.96

mln

- Company’s head office

South and Caucasus region

Regional representatives

National pharmacy distributors

Specialized distributors of nutritional supplements

Regional pharmacy distributors

RUB 83.80mln

RUB 42.60mln

RUB 58.92mln

RUB 119.01mln

RUB 252.15mln

RUB 130.88mln

RUB 1,548**

mln

(*) distributor’s share in the total sales for the year of 2009(**) total sales for the year of 2010Source: Company data

Independent drug-store chains

MOSCOW

ТOP-10 distributors Share*, %

CIA International 14.8%

Regional representatives 12.9%

Katren 10.6%

AMMA 9.9%

Rosta 8.4%

Apteka-Holding 7.7%

Protek 5.8%

Akonit 4.0%

Moron 2.8%

Interpan 2.6%

Total TOP-10 79.6%

Page 20: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

20

Vladimir TikhonovCEOOne of the Company’s founders, who manages it since its origin in 1994. Graduated from Moscow State Technical University n.a. Bauman in 1992 . Member of the Russian Academy of Natural Science

Experienced Management Team

The team of professionals with long-term experience in the market

Vladimir KozlovFirst Deputy CEOOne of the Company’s founders, Chairman of the Board of Directors. Graduated from Moscow Radiotechnics, Electronics and Automation Institute in 1991

Eduard ChernyshovForeign Economic Relations DirectorStarted his career in OJSC DIOD in the beginning of 1995. Graduated from All-Union Extramural Polytechnics Institute in 1989

Vadim SilantievSales and Marketing DirectorOccupies this position since the end of 2000. Graduated from All-Russian Extramural Financial-Economics Institute in 2002

Lubov Dergacheva Head of R&D DepartmentOccupies this position from September 2004. Graduated from Moscow State Medical University in 1984. Highest Quality Endocrinologist, specialist in restorative medicine, holds GSP certificate

Page 21: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

21

Best Corporate Governance Practices

Independent directorsCompany’s corporate structure

Consumer Healthcare Pharmaceutical Export

CJSC Ecologia Pitaniya

Nutriceutical production

Ecologia Zhizni, Ltd.

Distribution

OJSC DIODProduction

Nika Stroj. Ltd.Land plot

CJSC OlyfenProduction

CJSC AmetisCompounds production,

distribution

CJSC Vega PharmDistribution

Nika Servis, Ltd.Land plot

Flavir, Ltd.Compounds and raw taxifolin production

99%

70%

100%

100%

100%

51%

100%

Vitamedis AG Distribution

SIBLAREX Gruppa Kompanij Ltd.

Distribution

51%

50%

74%

V. TyurenkovIndependent Director■Private investor, consults several USA and Singapore investment funds. Worked as a management director of Hansberger Global Investors investment company, USA; OGK-4 Board Member; Open Investments Board Member Education:■Moscow State Technical University n.a. Bauman, graduate education in the Russian Academy of Science Institute of USA and Canada■Pepperdine University, USA, California (MBA)

E.FellIndependent Director■Worked as an employee of the Russian representative office of Hansberger Global Investors (USA)■Has a great experience at the high-tech companies■Education: Moscow Aviation Institute, Economist

Y.KuznetsovIndependent Director■Head of Industry Department of the Moscow Government (1992 – 2000)Education:■Kharkov Academy АRTA (1984)■Minsk Higher Engineer Technician Academy (1981)

Page 22: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

Strategy and directions of developmentSection 3

Page 23: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

23

Development Strategy

■ Retain 5-7% market share in consumer healthcare segment with annual market growth of 10-15%

■ Launch of 12-15 new products by 2013, with the goal of introducing 2-3 “blockbuster” products (with annual sales of $10-15 mln) .

■ Construction a new pharmaceutical plant as a joint venture with a large producer of generics and substances

■ Launch of:

- generics

- modernized generics (combined drugs)

- drugs production under Diod’s umbrella brands

- registration and launch of Diod’s healthcare products as branded drugs

Convert into a pharmaceutical company2

■ Besides drugstores, establish new partnerships with food retailers to sale consumer healthcare products and functional/medical nutrition

■ Tune the current distribution to sale new pharmaceuticals

■ Increase the share of sales by regional distribution partners and due to regional promoting

■ Export sales through partnerships with foreign pharmaceutical companies

Expand distribution network5

■ Increase sales CAGR up to 30-33% as a result of launching of pharmaceuticals and functional/medical nutrition

■ Reach EBITDA margin up to 35-40%

Increase sales and margins 6

Pharmaceuticals revenue share shall increase from 10% up to 50%

■ Launch of new forms of current products

■ Development and marketing new brands without material commercial costs

■ Use of nanotechnologies in the development of consumer healthcare products

Stabilize and retain the share of consumer healthcare products market

1

Launch of functional /medical nutrition

3

■ Use of current healthcare product substances for functional/medical nutrition

■ Marketing of functional/medical nutrition under Diod’s umbrella brands

■ Develop substances export for food, cosmetics, and consumer healthcare production

Export and production of substances

4

2010 2016

Page 24: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

24

Pipeline

Existing brands

New (innovative) products

2011

2012

2013

2011

2012

2013

2014

OTC (over-the-counter) Rx (prescription products)

OTC (over-the-counter) Rx (prescription products)

■ Antibacterial nose spray

■ Prevention and treatment of iodine deficit■ Decreasing of arterial blood pressure (antihypertensive

treatment)

■ Rheumatologic diseases and diseases of musculoskeletal system treatment

■ Antiviral product

■ Heart ischemia treatment

■ Children memory and attention enhancing treatment, immune system treatment

■ Weight control treatment■ Sexual dysfunction treatment

■ Cardio- and angioprotecting treatment

■ Neurological diseases’ treatment

■ Gynecopathy treatment and mastitis

■ Anti-inflammatory for rheumatism diseases treatment

■ Prostatitis treatment

■ Side effects of chemo- and radiotherapy treatment■ Prevention of thrombosis (hemoreologic treatment)

2015 ■ Antibacterial and immunostimulatory product ■ Osteoporosis treatment

Page 25: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

25

Sales and Marketing

Sales and promotion

■ Defining market trends, analysis of new attractive market segments

■ Development and implementation of efficient brands and advertising strategy

■ Implementation of customer loyalty and customer incentive programs

■ The Company has historically successfully launched new products, which were in great demand and addressed customers’ needs and demands

■ The Company makes substantial investments in marketing and advertising

Key initiatives of the marketing strategy of “DIOD”

Key elements of the brand strategy

■ 15-years’ comprehensive experience of partnership with leading mass media

■ Reputation of producer of efficient and secure products

■ Focus on unique technologies and original compounds

■ Creation of brands by umbrella pattern which will unite products of different product categories

■ 60-90 day delay of payment provided to distributors at 30% annual interest rate

■ Additional discounts, bonuses and incentive schemes

■ Recurrent marketing initiatives in order to increase customers’ interest to Company’s products

■ Target amount of advertising costs - 20% of total sales

Advertising expenses allocation, RUB mln

Source: Company data Source: Company’s management accounts for the year of 2009

Page 26: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

26

46%

35%

19%

1,200

1,000

400

Investment Program

Based on the Company’s investment program for 2010-2014.Source: Company data.

■ In order to enhance its market positions, the Company makes substantial investments in its business development

■ The Company has developed a comprehensive investment program for 2010 - 2014 with a total value RUB 2.6 bln ($84 mln)

■ These investments are aimed at growing DIOD’s market share, increasing its efficiency and capitalization

RUB 2,600 mln

Enhancing of market positions

Capital expenditure

Corporate structure optimization

Share issuing and company financing

Long-term loan resources

Bond issuing

RUB 2,600 mln

Investment program Financing sources

Steps TargetBudget, RUB mln

Expenditures

Capitalization of R&Ds

n

n

Conversion of healthcare products into pharmaceuticals

Development of specialized medical nutrition

Grow DIOD’s market share, increase efficiency and capitalization

1 200

u

u

u

Enhance positions in pharmaceutical segment

Development of innovative medical technologies

Enter into new market of health medical food

Capital expenditure

n Modernization of current and construction of new production facilities

Increase of production volume and reduction of costs

900

u

u

Build a new complex to relocate production and R&D facilities outside of Moscow

Modernization of existing production facilities in consumer health and pharmaceutical segments

Development and optimization of corporate structure

n Vertical and horizontal integration

Hedging of business risks and growth of the market share

500

u

u

Completion of current M&A deals

Strengthen of vertical integration through new acquisitions

Page 27: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

Key Financial IndicatorsSection 4

Page 28: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

28

Key Financial Indicators

Company’s key financial indicators

Source: Company’s audited consolidated IFRS financial statements for the years of 2007-2010

Revenue structure by segment, 2010

Source: Company’s audited financial statements for the year of 2010

Mln. rub.2007 2008 2009 2010

Revenue 1 624 1 730 1 559 1 548

Growth rate 14% 7% -10% -1%

Cost of Sales (671) (674) (726) (752)

Gross profit 953 1 056 833 796

Gross margin 59% 61% 53% 51%

SG&A and other expenses (527) (670) (529) (493)

R&D expenses (18) (17) (17) (12)

EBITDA 417 389 332 359

EBITDA margin 26% 23% 21% 23%

Operating profit 407 368 287 303

Operating margin 25% 21% 18% 20%

Net profit 232 303 374 163

Net margin 14% 17% 24% 11%

Net profit less M&A 229 200 109 131

Net margin less M&A 14% 12% 7% 8%

Total debt182 516 529 610

Net debt159 488 491 572

Page 29: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

29

Key Financial Parameters Dynamics

Revenue, RUB mln EBITDA, RUB mln

Investment expenditures*, RUB mln Net income, RUB mln

*According to the Cash Flow report for the years of 2007-2010

Source: Company’s audited consolidated IFRS financial statements for the years of 2007-2010

14%

7%

-10%

-1%

14%

12%

7%8%

26%

23% 21%23%

Page 30: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

30

Cost Structure and EBITDA

Cost structure, 2010 SG&A structure, 2010

EBITDA calculation, 2010 RUB mln

RUB 752 mln

RUB 481 mln

Source: Company’s audited IFRS financial statements

Labor

Tax

Fixed Assets depreciation and intangible assets amortization

Cost of purchased goods

OtherServices of outside organizations

Advertising expenses

Taxes

Labor expenses

Rent

Royalty

Page 31: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

31

Long-Term Growth Drivers

EBITDA 2008

EBITDA 2009

EBITDA 2013

Marketing expenses decrease

Market size decreases

Cost-cutting initiatives

Consumer healthcare market

growth

Launch of new products under existing brand

names

Launch of new products and

brands

Page 32: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

Financial Statements for the Years of 2007-2010Appendix 1

Page 33: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

33

Income Statement for the Years of 2007-2010

Source: Company’s audited consolidated IFRS financial statements for the years of 2007-2010

Mln. rub. 2007 2008 2009 2010

Revenue 1 624 1 730 1 559 1 548

growth rate % 14% 14% 14% 14%

COGS (671) (674) (726) (752)

Gross profit 953 1 056 833 796

Sales expenses (396) (516) (369) (332)

G&A expences (131) (154) (160) (150)

R&D expenses (18) (17) (17) (12)

Operating profit 407 368 287 303

Other income 7 154 292 46

Other expenses (74) (65) (56) (92)

Earnings before taxes 333 408 410 165

Income tax (101) (106) (46) (35)

Net income 229 303 364 130

Payments after taxes      

Retained earnings per annum 232 303 364 130

Minority Interest 3 0 -10 -33

Shareowners’ Profit 229 303 374 163

Weighted Average Shares Outstanding perannum

91 500 000 91 500 000 91 500 000 91 500 000

Earnings per Share (in RUR per share). Basic. 2,50 3,31 4,08 1,78

Page 34: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

34

Balance Sheet for the Years of 2007 - 2010

Source: Company’s audited consolidated IFRS financial statements for the years of 2007-2010

Mln. rub. 2007 2008 2009 2010

Assets  

NON-CURRENT ASSETS:

Fixed assets 384 401 443 452

Investment property 0 0 1 1

Goodwill 215 266 268 266

Intangible assets 4 478 1 100 1 160

Financial assets for sale 0 0 0 0

Other financial assets 9 19 1 0

Long-term accounts receivable

16 28 0 0

Deferred taxes 29 33 46 51

Non-current assets held for sale

11 0 0 0

Total non-current assets 6671 226 1 860 1 931

CURRENT ASSETS:

Inventories 336 578 639 570

Accounts receivable 496 493 548 797

Loans 53 21 16 21

Cash and cash equivalents 23 29 38 38

Total current assets 9081 121 1 241 1 425

TOTAL ASSETS 1 5742 347 3 101 3 356

Mln. rub. 2007 2008 2009 2010

EQUITY

Shareowners' equity 1 1 1 1

Revaluation reserve 280 285 285 279

Retained earnings 808 1 082 1 429 1 544

Total Capital pertaining to the Mother Company Capital

1 089 1 368 1 709 1 824

Minority interest 11 57 296 350

Total equity 1 100 1 425 2 005 2 174LIABILITIES

Non-current liabilities

Long-term loans and liabilities

0 310 76 381

Deferred taxes 73 152 281 295

Long-term accounts payable 0 0 21 14

Total non-current liabilities

73 462 379 691CURRENT LIABILITIES:

Loans 182 206 453 229

Accounts payable 21 91 158 146

Other accounts payable 106 46 0 24

Reserves 10 42 45 40

Tax liabilities 84 74 62 51

Total current liabilities 402 459 718 491TOTAL LIABILITIES 475 922 1 096 1 182TOTAL EQUITY AND LIABILITIES

1 574 2 347 3 101 3 356

Page 35: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

35

Cash Flow Statement for the Years of 2007-2010

Source: Company’s consolidated IFRS financial statements for the years of 2007 - 2010

Mln. rub. 2006 2007 2008 2009 2010

Current activities:          

Cash from buyers and customers 1 822 1 638 2 028 1 756 1 578

Other revenues 1 372 1 11 12

Cash used to pay for:

Purchased goods, services, raw materials and other current assets

-1 242 -1 134 -1 474 -1 039 -988

Labor -180 -181 -248 -226 -212

Dividends and interests -27 -67 -49 -99 -91

Taxes and duties including income tax

-289 -250 -352 -308 -300

Other expenses -157 -239 -10 -19 -22

Cash Flows from Operations, net

-73 140 -103 74 -23

Mln. rub. 2006 2007 2008 2009 2010

Investing activities:          

Proceeds from fixed assets sales and other non-current assets sales

0 0 66 0 0

Proceeds from sale of securities and other financial investments

0 0 1 0 0

Interest earned 0 1 1 0 1

Redemption of loans provided to other companies

0 9 9 47 15

Affiliated companies acquisition 0 -140 -55 -37 -51

Fixed assets acquisition and other investments into commodities and intangible assets

0 -2 -34 -22 -18

Acquisition of securities and other financial investments

0 -10 -200 -1 -3

Loans provided to other companies 0 -24 -15 -17 -8

Cash Flows from Investment Activities, net

0 -166 -227 -30 -63

Financial activities          

Loss from Currency Purchase 0 0 -1 -1 0

Proceeds from issue of shares or other equity securities

0 0 0 0 0

Loans and Credits repaid 0 30 1 494 1 129 1 271

Repayment of loans and credits (without interest)

0 -3 -1 144 -1 140 -1 182

Dividends paid 0 0 -13 -24 -10

Subsidies 0 0 0 1 7

Cash Flows from Financing Activities, net

0 27 336 -35 86

Net Cash Increase (Decrease) -73 0 5 10 0

End of the Year Balance5 24 29 38 38

Page 36: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

Key Financial Parameters ForecastAppendix 2

Page 37: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

37

Key Financial Parameters Forecast

Revenue forecast in nutrition supplements, RUB mln Revenue forecast in clinical nutrition, RUB mln

Revenue forecast in pharmaceutical sector, RUB mln Revenue dynamics, EBITDA & net income, RUB mln

Source: Company data

Page 38: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

Company’s Product PortfolioAppendix 3

Page 39: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

39

Product Portfolio*

Consumer healthcare products

Medical nutrition Health cosmetics Branded generics Original products

Cardiovascular

CapillarCapillar-cardioCapillar 120/80ArmakorSelen-Aktiv

Capillar cardioCapillar 120/80

Capillar balm creamCapillar leg balm

Капилар ЭналаприлКапилар Бета-блокатор

GipoksenCapillar forteDikvertinSalivertin

NeurologicalNurovenaOil extract with ataractic effect

Ataractic teaActivny Den Tea

AskovertinMebixCapilashka

Arthrological

Artro-Aktiv blistersArtro-Aktiv alimentary pills

Artro-Aktiv alimentary Artro aktiv warmingArtro aktiv alimentary

Артро актив НемесулидАртро актив Диклофенак

Artro Aktiv forte antiphogisticArtro Aktiv forte reconstructiveArtro strong

Antiviral and antibacterial

Araglin DBronhodiolPulmo Aktiv

Flu treatment Tooth paste Георгий спрей для носа Орвирем таблетка

OrviremArbistrong

Oncologic Basidial mushrooms Khimdetox

Gynaecological Stella Stella Georgy silver ion water ionizer Stella parm

OphthamologyOkulistOkulist-chernikaOkulist-lutein

Okulist Tonic Okulist Okulisty forte

Weight control

Phase 1 Phase 2Phase 4 (Bloker of sweets)

Phase 0 Phase 1 (olean)Phase 3Cosmossup

Phase 3 forte

Women’s reproductive health

Е-AktivQ10-AktivIod-AktivIod-Aktiv forteDolgoletL-karnitin

Iod-Aktiv standard Calcium srtrong

Men’s sexual healthViardoViardo-forte

Viardo-max Prostatcel

(*) Indicated by colors as follows: registered brands, products under registration, planned products

Page 40: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

40

Established Partnership With Research Institutes and Associations

■ The Company has sufficient capabilities to develop new pharmaceutical and consumer healthcare products building partnership with leading research institutes

■ The Company has established partnership with 53 research institutes and 8 professional associations, including:

Belgorod State University (nanocenter)

State Research University of the Russian Academy of Medical Sciences (“RAMS”) of pharmacology n.a. Zakusov

Russian Oncology Scientific Center of RAMS n.a. N.N. Blokhin

Moscow Medical Academy n.a. I.M. Sechenov

Russian Cardiologic Scientific Institute

Russian State Medical University

Moscow Pediatric Surgery Research Institute

Russian Center of Reconstructive and Spa Medicine

Flu Research Institute of RAMS (St. Petersburg)

Russian Chemical-Engineering University n.a. D.I. Mendeleev

Association of Restorative Medicine

Russian Association of Children Oculists

Russian Association of Obstetrician-Gynecologist

National Association of Dietarians and Threpsologists

R&D partnerships in different sectors

15

12

9

8

8

8

7

6

5

4

Cardiovascular

Antiviral

Women's health

Oncological

Arthrological

Neurological

Ophthalmology

Weight control

Men's sexual health

Gynaecological

Page 41: Company’s Presentation August 2011. 1 204/255/153 0/93/15 48/48/48 204/204/204 234/234/234 128/128/128 255/204/102 255/255/204 165/0/33 Disclaimer This

41

IMPORTANT NOTICENeither this document nor any copy hereof may be sent or taken or transmitted into the United States, Canada, Australia or Japan or distributed, directly or indirectly, in the United States, Canada, Australia or Japan. Any failure to comply with this restriction may constitute a violation of U.S., Canadian, Australian or Japanese securities laws.

Contacts

DIOD OJSC

11A Derbenevskaya Str.Moscow 115114Russia

phone: +7 (499) 235-2151e-mail: [email protected]